BPC-157 for Gut Health: IBS, Leaky Gut, Ulcers - What Studies Show

Key takeaways

• There is no human study of BPC-157, oral or injected, in any gut condition: not ulcers, not colitis or Crohn's disease, not IBS, not 'leaky gut'.
• In rats, BPC-157 healed experimental stomach lesions, chemically induced colitis and surgically created fistulas, at 10 mcg/kg and even 10 ng/kg, by injection or in drinking water. Nearly all of those studies come from the Zagreb laboratory that discovered the peptide.
• We found no animal or human study of BPC-157 in IBS and none that measured intestinal permeability, so the IBS and 'leaky gut' claims have no data of any kind behind them.
• 'Leaky gut' is a research measurement, not an established diagnosis, and a Mayo Clinic review notes that restoring barrier function has not been shown to improve any gut or body-wide disease.
• No US pharmacy may compound BPC-157 as of October 2026. For a real gut problem, the treatments with human trials are available on prescription.

The direct answer: BPC-157 has never been tested in a person with a gut problem, by mouth or by injection. Its gut reputation rests on rat studies of ulcers, colitis and fistulas, almost all from one laboratory, and on the fact that it survives stomach acid, which is why it is sold as capsules. There is no study of it in IBS, and none that measured 'leaky gut'. This article is part of our evidence review of peptides for gut health and inflammation; the capsule question is covered in oral BPC-157 vs injection, and the full compound profile, with safety and legal history, is in BPC-157.

The evidence, condition by condition

Grade D under our editorial policy means animal or laboratory data only, or no evidence at all. Every row here is D.

What the rat studies show, and what they cannot

The rodent results are consistent within their design. In the fistula studies, rats had a hole made between the colon or stomach and the skin and were treated from 30 minutes after surgery; BPC-157 closed the defects faster than controls whether it was injected or dissolved in drinking water, and it did so at doses a thousand-fold apart (Klicek 2008). In the colitis study, cysteamine was given into the rectum to injure the colon, and BPC-157 healed both the colitis and a surgical join in the same animals (Klicek 2013). In the persistent-ulcer model, it outperformed ranitidine, omeprazole and atropine (Skorjanec 2009).

Three cautions apply to all of them. They are acute chemical or surgical injuries in young healthy rats, treated from the moment of injury; ulcerative colitis and Crohn's disease are chronic immune diseases that wax and wane over years. The same benefit at 10 micrograms and 10 nanograms per kilogram is unusual pharmacology that has not been explained. And the work comes overwhelmingly from one group, the one that also describes the peptide in its paper titles as being 'in clinical trials' for inflammatory bowel disease, a program under the code PL 14736 whose results were never published.

The oral detail matters for the search that brought you here. In these rats, drinking water worked as well as injection, which suggests a local effect on the gut lining is possible. That is a rat result: a 2026 drug-development review found no human pharmacokinetic data for oral BPC-157 and no pharmaceutical-grade formulation of any kind (Mateescu 2026). The oral vs injection article explains why survival in stomach acid does not settle the question.

No human gut trial

As of October 2026 there is no published or results-posting human trial of BPC-157 in any gut condition. The published human studies are three uncontrolled pilots from one Florida clinic, covering knee pain, interstitial cystitis and intravenous safety, with fewer than 30 people in total (Mateescu 2026). BPC-157 was nominated to FDA's compounding list with ulcerative colitis as the proposed use; FDA's staff opposed it, citing, across the peptides reviewed, insufficient or nonexistent human trial data, uncertain identity and composition, and immunogenicity (Kelley Drye 2026). The advisory committee voted 8-6-1 in favor on July 23, 2026, but FDA has published no rule, so no US pharmacy may compound it; the legal tracker records every step.

'Leaky gut': a research measure, not a diagnosis

Intestinal permeability is real and measurable. Researchers test it by having a person drink probe molecules, typically two sugars of different sizes, and measuring how much appears in the urine, or by studying biopsies in the laboratory. Permeability rises with endurance exercise, anti-inflammatory painkillers, pregnancy, bile acids and some food emulsifiers, and it is increased in inflammatory and ulcerating bowel diseases (Camilleri 2019).

'Leaky gut syndrome' as sold online is something else: a catch-all explanation for fatigue, bloating, skin problems and food reactions, offered with a supplement to 'seal' the gut. The Mayo Clinic review written for clinicians makes two points that matter here. Claims about a 'leaky gut' in the public domain need confirmation before anyone endorses exclusion diets or supplements to repair it. And while inflammatory diseases make the gut leaky, no such disease is cured by normalizing the barrier, and it remains unproven that restoring barrier function improves any gut or body-wide disease (Camilleri 2019).

For BPC-157 the gap is wider still. The one paper that links it to permeability is a review, co-authored by the discovering laboratory's lead investigator, that proposes BPC-157 could counter painkiller-induced 'leaky gut syndrome' (Park 2020). We found no study, in animals or people, that gave BPC-157 and then measured permeability. Larazotide, a peptide built specifically to tighten the gut barrier, went through proper trials in celiac disease and still did not reach approval; the parent guide tells that story.

IBS: nothing to go on

IBS is a disorder of gut-brain interaction, diagnosed by symptom pattern after a few targeted tests, and it does not involve the kind of tissue injury the rat models create. We found no study of BPC-157 in IBS or in an animal model of visceral pain. Marketing that promises IBS relief is extrapolating from rat colitis to a different condition.

What to do instead

• Stomach pain, ulcers or reflux: see a clinician. Most ulcers are caused by H. pylori infection or anti-inflammatory painkillers, and testing for and treating the cause, stopping the painkiller where possible and acid suppression heal most of them.
• Diagnosed ulcerative colitis or Crohn's disease: the guideline-graded therapies a gastroenterologist prescribes are summarized in the parent guide. Do not stop or substitute them, and tell your gastroenterologist about anything you add.
• IBS-type symptoms: the ACG guideline suggests celiac serology and fecal calprotectin in people with diarrhea to rule out other disease, recommends a limited trial of a low-FODMAP diet and specific drugs for constipation-predominant or diarrhea-predominant IBS, and suggests gut-directed psychotherapy (Lacy 2021).
• Red flags: bleeding, weight loss, anemia, night-time symptoms, a family history of IBD or colon cancer, or new symptoms after 50 need prompt evaluation, not a peptide.
• If a clinic offers BPC-157 capsules or injections for your gut: ask which pharmacy, in which state, on what legal basis. In October 2026 there is no good answer.

Bottom line

BPC-157's gut story is a strong rat story and a blank human one. It healed experimental ulcers, colitis and fistulas in one laboratory's models, by injection and in drinking water. It has never been tested in a human gut, has no IBS data and no permeability data, and cannot be legally compounded in the United States. If your gut is the problem, the treatments that have been tested in people are where to start, and a capsule of unverified research peptide is not one of them.

Frequently asked questions

+−Is BPC-157 good for gut health?

In rats, it repeatedly protected and healed the stomach and bowel in experimental ulcers, colitis and fistulas, almost always in studies from the laboratory that discovered it. In people, it has never been tested for any gut condition: the entire human record is three small uncontrolled pilots in knee pain, interstitial cystitis and intravenous safety. A Croatian company's inflammatory bowel disease program never published results.

+−Does oral BPC-157 work for gut health?

In rats, BPC-157 dissolved in drinking water healed experimental colitis and fistulas about as well as injections, which is the basis for capsules. Whether a capsule does anything in a human gut has never been studied, the one registered study of oral tablets never reported results, and what commercial capsules contain has not been independently verified. Our oral versus injection article covers the details.

+−Can BPC-157 help leaky gut?

There is no study, in animals or people, that measured intestinal permeability after BPC-157. A 2020 review co-authored by the discovering laboratory proposes that it could counter permeability caused by anti-inflammatory painkillers, but that is a hypothesis. 'Leaky gut syndrome' as sold online is also not an established diagnosis; permeability is a research measurement, and restoring it has not been shown to cure any disease.

+−Does BPC-157 help IBS?

We found no study of BPC-157 in IBS, in animals or humans. The marketing borrows from rat studies of chemical colitis and ulcers, which are inflammatory injuries; IBS is a disorder of gut-brain interaction without that kind of tissue damage. The ACG guideline lists the treatments with evidence: a limited low-FODMAP trial, specific drugs for constipation or diarrhea, and gut-directed psychotherapy.

+−Can BPC-157 heal stomach ulcers?

It healed experimental stomach lesions in rats and, in one model, closed persistent stomach-to-skin fistulas faster than ranitidine, omeprazole or atropine. No human ulcer trial exists. Human ulcers are usually caused by H. pylori infection or anti-inflammatory painkillers, and testing and treating the cause, plus acid suppression, heals most of them.

+−How long does it take for BPC-157 to work in the gut?

Unknown in people, because no human gut study exists. In rats, effects were reported from the first days to about four weeks of daily dosing that started within an hour of a surgically created injury, which is not the situation of anyone with a long-standing gut complaint. Timelines quoted by sellers are not based on human data.

+−Can I take BPC-157 with my IBD medication?

No study has looked at BPC-157 alongside any IBD drug, and the products sold online are research chemicals of unverified content. Do not stop or replace prescribed therapy, and tell your gastroenterologist about anything you add, because an unknown substance complicates the reading of a flare or an abnormal blood test.

Sources

1. StudySkorjanec S et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. Dig Dis Sci 2009;54:46-56. (2009)
2. StudyKlicek R et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol 2013;64:597-612. (2013)
3. StudyKlicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008;108:7-17. (2008)
4. ReviewPark JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection. Curr Pharm Des 2020;26:2971-81. (2020)
5. ReviewCamilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 2019;68:1516-26. (2019)
6. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
7. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know (proposed use for BPC-157: ulcerative colitis). July 30, 2026. (2026)
8. GuidelineLacy BE et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021;116:17-44. (2021)